第 3 组肺动脉高压：从基础到临床。
Group 3 Pulmonary Hypertension: From Bench to Bedside.
机构信息
Division of Pulmonary, Critical Care and Sleep Medicine (N.S., C.E.V.), Brown University, Providence, RI.
Department of Pathology, Universities of Giessen and Marburg Lung Center (UGMLC), Justus-Liebig University, Germany (P.D.).
出版信息
Circ Res. 2022 Apr 29;130(9):1404-1422. doi: 10.1161/CIRCRESAHA.121.319970. Epub 2022 Apr 28.
Abstract
Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3 PH in the most recent classification system. Prevalence of these diseases is increasing over time, creating a growing need for effective therapeutic options. Recent approval of the first pulmonary arterial hypertension therapy for the treatment of Group 3 PH related to interstitial lung disease represents an encouraging advancement. This review focuses on molecular mechanisms contributing to pulmonary vasculopathy in chronic hypoxia, the pathology and epidemiology of Group 3 PH, the right ventricular dysfunction observed in this population and clinical trial data that inform the use of pulmonary vasodilators in Group 3 PH.
摘要
慢性肺部疾病引起的肺动脉高压（PH）在最新的分类系统中被归类为第 3 组 PH。这些疾病的患病率随着时间的推移而增加，因此需要有效的治疗选择。最近批准了第一种肺动脉高压治疗药物，用于治疗与间质性肺病相关的第 3 组 PH，这是一个令人鼓舞的进展。这篇综述重点介绍了慢性缺氧导致肺血管病变的分子机制、第 3 组 PH 的病理学和流行病学、该人群中观察到的右心室功能障碍以及临床试验数据，这些数据为第 3 组 PH 中使用肺血管扩张剂提供了信息。
相似文献
1
Group 3 Pulmonary Hypertension: From Bench to Bedside.
Circ Res. 2022 Apr 29;130(9):1404-1422. doi: 10.1161/CIRCRESAHA.121.319970. Epub 2022 Apr 28.
2
Pulmonary hypertension in parenchymal lung disease.
Heart Fail Clin. 2012 Jul;8(3):461-74. doi: 10.1016/j.hfc.2012.04.010.
3
Hypoxia- and non-hypoxia-related pulmonary hypertension - established and new therapies.
Cardiovasc Res. 2006 Oct 1;72(1):30-40. doi: 10.1016/j.cardiores.2006.07.025. Epub 2006 Aug 1.
4
A case of glucocorticoid-resistant adult Still's disease complicated by pulmonary hypertension and interstitial lung disease.
Mod Rheumatol Case Rep. 2023 Jan 3;7(1):182-187. doi: 10.1093/mrcr/rxac081.
5
Pulmonary hypertension in chronic lung disease and hypoxia.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01914-2018. Print 2019 Jan.
6
Pulmonary hypertension secondary to interstitial lung disease.
Expert Rev Respir Med. 2011 Apr;5(2):179-89. doi: 10.1586/ers.11.11.
7
Pulmonary hypertension and right heart dysfunction in chronic lung disease.
Biomed Res Int. 2014;2014:739674. doi: 10.1155/2014/739674. Epub 2014 Jul 24.
8
Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia.
BMC Pulm Med. 2017 Apr 11;17(1):58. doi: 10.1186/s12890-017-0399-1.
9
Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29.
10
Current management of patients with pulmonary hypertension and right ventricular insufficiency.
Curr Cardiol Rep. 2000 May;2(3):244-51. doi: 10.1007/s11886-000-0075-5.
引用本文的文献
1
Integrating CT-Based Lung Fibrosis and MRI-Derived Right Ventricular Function for the Detection of Pulmonary Hypertension in Interstitial Lung Disease.
J Clin Med. 2025 Jul 28;14(15):5329. doi: 10.3390/jcm14155329.
2
Opposing roles for myeloid and smooth muscle cell STING in pulmonary hypertension.
JCI Insight. 2025 May 22;10(13). doi: 10.1172/jci.insight.184792. eCollection 2025 Jul 8.
3
A Prospective Analysis of Vasoreactivity and Mortality in WHO Group 3 Pulmonary Hypertension.
Pulm Circ. 2025 Apr 17;15(2):e70078. doi: 10.1002/pul2.70078. eCollection 2025 Apr.
4
TBX4 in Pulmonary Hypertension: Linking Lung Development to Precision Therapy.
Am J Respir Cell Mol Biol. 2025 Sep;73(3):340-342. doi: 10.1165/rcmb.2025-0164ED.
5
Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
J Clin Med. 2025 Mar 17;14(6):2029. doi: 10.3390/jcm14062029.
6
Oral Pulmonary Arterial Hypertension-Targeted Therapy in Patients With Pulmonary Hypertension due to Interstitial Lung Disease.
J Clin Med Res. 2025 Mar;17(3):153-163. doi: 10.14740/jocmr6164. Epub 2025 Mar 10.
7
[Diagnosis and Treatment of Pulmonary Embolism and Pulmonary Hypertension in Patients With Interstitial Lung Disease].
Open Respir Arch. 2025 Feb 6;7(1):100406. doi: 10.1016/j.opresp.2025.100406. eCollection 2025 Jan-Mar.
8
Will Stub1 Be the Next Target for Pulmonary Hypertension Therapy Development?
Am J Respir Cell Mol Biol. 2025 Sep;73(3):329-331. doi: 10.1165/rcmb.2025-0034ED.
9
Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment.
Pharmaceutics. 2025 Feb 10;17(2):224. doi: 10.3390/pharmaceutics17020224.
10
Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.
Int J Mol Sci. 2025 Jan 20;26(2):835. doi: 10.3390/ijms26020835.
本文引用的文献
1
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial.
Am J Respir Crit Care Med. 2022 Jan 15;205(2):198-207. doi: 10.1164/rccm.202107-1766OC.
2
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
J Heart Lung Transplant. 2021 Nov;40(11):1349-1379. doi: 10.1016/j.healun.2021.07.005. Epub 2021 Jul 24.
3
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry.
Eur Respir J. 2021 Aug 26;58(2). doi: 10.1183/13993003.01483-2021. Print 2021 Aug.
4
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
Lancet Respir Med. 2021 Nov;9(11):1266-1274. doi: 10.1016/S2213-2600(21)00165-X. Epub 2021 Jun 29.
5
Elevated pulmonary vascular resistance predicts mortality in COPD patients.
Eur Respir J. 2021 Aug 26;58(2). doi: 10.1183/13993003.00944-2021. Print 2021 Aug.
6
Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
Chest. 2021 Aug;160(2):678-689. doi: 10.1016/j.chest.2021.02.012. Epub 2021 Feb 11.
7
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
N Engl J Med. 2021 Jan 28;384(4):325-334. doi: 10.1056/NEJMoa2008470. Epub 2021 Jan 13.
8
Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension.
Circ Genom Precis Med. 2020 Dec 15;14(1):e003155. doi: 10.1161/CIRCGEN.120.003155.
9
'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.
Genes (Basel). 2020 Nov 26;11(12):1408. doi: 10.3390/genes11121408.
10
Pulmonary Artery Endovascular Device Compensates for Loss of Vascular Compliance in Pulmonary Arterial Hypertension.
J Am Coll Cardiol. 2020 Nov 10;76(19):2284-2286. doi: 10.1016/j.jacc.2020.08.080.
Zotero 插件